Embracing Longevity and Wellness: CV Health in Cancer Survivors with Advanced Disease

Join Dr Susan Dent (President of IC-OS, University of Rochester, US), Dr Farhan Bajwa (Strong Memorial Hospital, US), Dr Dan Lenihan (Saint Francis Healthcare System, US) and Dr Joe Carver (University of Pennsylvania, US) as they explore cardiovascular health in cancer survivors with advanced disease.

Cancer survivors with advanced disease face unique cardiovascular challenges that impact their long-term health. This webinar brings together experts to discuss the latest strategies for preserving cardiac function, mitigating treatment-related risks, and improving overall wellness. Led by experts in the field, this webinar will provide valuable insights into optimising longevity and quality of life in this high-risk population.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BeiGene, BMS/Pfizer Alliance, Eli Lilly and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.